LANNETT CO INC (LCI) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:LCI - US5160122009 - Common Stock
LCI Key Statistics, Chart & Performance
The current stock price of LCI is 0.6855 USD. In the past month the price decreased by -59.68%. In the past year, price decreased by -74.42%.
LCI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.37 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.69 | 492.44B | ||
| MRK | MERCK & CO. INC. | 12.55 | 274.34B | ||
| PFE | PFIZER INC | 7.96 | 144.87B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.72B | ||
| ZTS | ZOETIS INC | 20.06 | 56.04B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.77 | 23.19B | ||
| VTRS | VIATRIS INC | 5.48 | 14.70B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.45 | 11.66B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.54B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.53B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.05B |
Related stock screener links
About LCI
Company Profile
Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. The company is headquartered in Trevose, Pennsylvania and currently employs 564 full-time employees. The company went IPO on 2002-04-15. The firm markets approximately 100 products, mainly tablet, capsule or liquid oral generic medications. Its marketed products include generics such as Posaconazole, Fluphenazine, Levothyroxine, Sumatriptan and NDA-based product Numbrino. The Company’s product portfolio include Amphetamine IR Tablets, which are used to treat Attention deficit hyperactivity disorder (ADHD) and narcolepsy; Dicyclomine tablets, used for the treatment of functional bowel disorder and irritable bowel syndrome; Levothyroxine Capsules, used to treat patients with hypothyroidism and other conditions, and Numbrino Nasal Solution, used for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults, among others.
Company Info
LANNETT CO INC
1150 Northbrook Drive, Suite 155
Trevose PENNSYLVANIA 19136 US
CEO: Timothy C. Crew
Employees: 564
Phone: 12153339000.0
LANNETT CO INC / LCI FAQ
Can you describe the business of LANNETT CO INC?
Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. The company is headquartered in Trevose, Pennsylvania and currently employs 564 full-time employees. The company went IPO on 2002-04-15. The firm markets approximately 100 products, mainly tablet, capsule or liquid oral generic medications. Its marketed products include generics such as Posaconazole, Fluphenazine, Levothyroxine, Sumatriptan and NDA-based product Numbrino. The Company’s product portfolio include Amphetamine IR Tablets, which are used to treat Attention deficit hyperactivity disorder (ADHD) and narcolepsy; Dicyclomine tablets, used for the treatment of functional bowel disorder and irritable bowel syndrome; Levothyroxine Capsules, used to treat patients with hypothyroidism and other conditions, and Numbrino Nasal Solution, used for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults, among others.
What is the current price of LCI stock?
The current stock price of LCI is 0.6855 USD. The price increased by 3.86% in the last trading session.
What is the dividend status of LANNETT CO INC?
LCI does not pay a dividend.
How is the ChartMill rating for LANNETT CO INC?
LCI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Would investing in LANNETT CO INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LCI.
Can you provide the number of employees for LANNETT CO INC?
LANNETT CO INC (LCI) currently has 564 employees.
Can you provide the market cap for LANNETT CO INC?
LANNETT CO INC (LCI) has a market capitalization of 7.38M USD. This makes LCI a Nano Cap stock.
LCI Technical Analysis
LCI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to LCI. Both the profitability and financial health of LCI have multiple concerns.
LCI Financial Highlights
Over the last trailing twelve months LCI reported a non-GAAP Earnings per Share(EPS) of -6.44. The EPS decreased by -129.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
LCI Forecast & Estimates
9 analysts have analysed LCI and the average price target is 4.08 USD. This implies a price increase of 495.19% is expected in the next year compared to the current price of 0.6855.
For the next year, analysts expect an EPS growth of -3.01% and a revenue growth -11.78% for LCI